Back to Trials
NCT06445439NARecruiting

Optimal Pacing Rate for Cardiac Resynchronization Therapy

Medstar Health Research Institute

Start Date

12/19/2023

Completion Date

8/1/2025

Summary

This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa.

Detailed Description

Cardiac resynchronization therapy (CRT) after atrioventricular node (AVN) ablation for permanent atrial fibrillation (AF) has led to better outcomes in heart failure (HF) patients with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF) compared to pharmacotherapy. Emerging evidence has demonstrated patients with HFpEF may benefit from a higher heart rate compared to standard heart-lowering therapies. The optimal pacing rate for CRT after AVN ablation in persistent AF and HFpEF remains unknown. This is a prospective, randomized crossover study. The objective of the study is to determine if a pacing rate of 80 beats per minute (bpm) improves exercise tolerance during the 6-minute walk test. The investigators will randomly assign half of the participants to a starting rate of 60 bpm and then switch them to a rate of 80 bpm for 3 months, and vice versa. Patient mortality and HF hospitalizations will be recorded at each phase. An electrocardiogram, echocardiogram, pacemaker interrogation, BNP and creatinine levels, KCCQ-12, six-minute walk test, and physical activity measure will be obtained at baseline, 3 months, and 6 months.

Eligibility Criteria

Age Range: 18 years to 90 years

Inclusion Criteria: 1. Age 18 years or older 2. History of persistent or permanent atrial fibrillation 3. Implantation of CRT or conduction system pacing in prior 3 months to 5 years of study start 4. History of intrinsic AVN block or have undergone AVN ablation in prior 3 months to 5 years of study start 5. LVEF ≥ 50% 6. N-terminal pro-B-type natriuretic peptide (NT-proBNP) \>400 pg/mL in the last 24 months 7. Clinical HF diagnosis or NYHA class II or higher 8. Able to provide informed consent Exclusion Criteria: 1. LVEF \<50% 2. Wide QRS (greater than 150ms) 3. Isolated RV pacing 4. Severe valvular disease 5. Severe coronary artery disease as defined by one of the following: 1. ACS or PCI within 1 year 2. Any angina (CCS class 1+) 3. Unrevascularizable severe CAD (\>70% stenosis in 1+ major vessels and/or based on functional assessment) 6. ESRD 7. Significant primary pulmonary disease on home oxygen 8. Major orthopedic issues, such as being wheelchair bound and/or unable to perform a six-minute walk test 9. Ventricular ectopy \>15% premature ventricular contractions (PVC) 10. End stage cancer diagnosis 11. Life expectancy less than one year 12. Palliative or hospice care 13. Hypertrophic cardiomyopathy (HCM) 14. Uncorrected ventricular septal defect 15. Infiltrative cardiomyopathy (CM) 16. Uncontrolled hypertension as defined by blood pressure \>160/100 mm Hg on two measurements ≥15 minutes apart 17. Hemoglobin \<7 g/dL 18. Age \>90 years old 19. Pregnant or intends to become pregnant

Interventions

DEVICE

Pacing rate of 80 bpm

DEVICE

Pacing rate of 60 bpm

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Atrial Fibrillation, Persistent

Locations

MedStar Georgetown University Hospital

Washington D.C., District of Columbia 20007

United States

MedStar Washington Hospital Center

Washington D.C., District of Columbia 20010

United States

MedStar Union Memorial Hospital

Baltimore, Maryland 21218

United States

MedStar Southern Maryland Hospital

Clinton, Maryland 20735

United States

MedStar Heart and Vascular Office at Fairfax

Fairfax, Virginia 22031

United States